Oncolytics Biotech ( (TSE:ONC) ) has provided an announcement.
On February 7, 2025, Oncolytics Biotech announced that CEO Matt Coffey, Ph.D., will not return following a medical leave due to health concerns. Dr. Coffey, a co-founder who played a pivotal role in advancing pelareorep from pre-clinical stages to successful Phase 2 studies, decided to step down as CEO. Wayne Pisano, Chair of the Board, will serve as Interim CEO while the company searches for a new leader to continue advancing its innovative cancer treatments. This leadership change marks a significant transition for Oncolytics as it continues to develop its promising therapeutic agent, pelareorep, in the oncology sector.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent for oncology. The company has demonstrated promising results in Phase 2 studies for metastatic breast cancer and pancreatic cancer, working towards registrational studies with Fast Track designation from the FDA.
YTD Price Performance: -16.36%
Average Trading Volume: 1,234,977
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $58.55M
Find detailed analytics on ONC stock on TipRanks’ Stock Analysis page.